GL1X · GenesisL1 explorer

Research workbench

Scaffold focused virtual screening: prospective application to the discovery of ttk inhibitor

Analyse Scaffold focused virtual screening: prospective application to the discovery of… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4BI1
Type
protein
Length
252 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Dual specificity protein kinase ttk
EC
2.7.12.1
UniProt
P33981
Ligands
ZO6
Pockets
1 · best druggability 0.66

Structure

x-ray diffraction · 1 distinct chain · 38% helix, 21% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ADual specificity protein kinase ttk (EC 2.7.12.1)protein25238% helix, 21% strandP33981

Ligands and binding sites

  • ZO6 · thieno[3,2-c][2,6]naphthyridine · ligand · chains A
  • 7PE · 2-(2-(2-(2-(2-(2-ethoxyethoxy)ethoxy)ethoxy)ethoxy) ethoxy)ethanol · additive · 4 copies · chains A
  • EDO · 1,2-ethanediol · additive · 4 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14240.660.79417PE, ZO6

Compared structures

  • 4BI1 · Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.